- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07444866
Maskinlæringsbasert håndtering av atferdsmessige og psykologiske symptomer på demensintervensjon for demensomsorgspersoner
Utvikling og testing av en maskinlæringsbasert håndtering av atferdsmessige og psykologiske symptomer på demensintervensjon for omsorgspersoner til personer med demens: En hybrid eksperimentell designstudie
Develop and test a machine learning enabled management of behavioural and psychological symptoms of dementia intervention for dementia caregivers.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Hong Kong, Hong Kong
- The Education University of Hong Kong
-
Ta kontakt med:
- Kee Lee Chou, PhD
- Telefonnummer: +85229487473
- E-post: klchou@eduhk.hk
-
Ta kontakt med:
- Vivien Tang, MSc
- E-post: s1135125@s.eduhk.hk
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- aged 18 above
- family caregiver of an individual with a confirmed medical diagnosis of any type of dementia who has been residing in the community
- having been providing care for ADLs and IADLs for at least 20 hours per week for at least one year prior to recruitment
- have a smartphone
- have mild to moderate stress (the 14-item Chinese version Perceived Stress Scale).
Exclusion Criteria:
- having participated in any structured mind-body intervention, cognitive therapy, or structured psychosocial intervention in the 6 months prior to recruitment
- having acute psychiatric and medical comorbidities that are potentially life-threatening (e.g. suicidal ideation) or that limit the caregivers' participation or adherence (e.g. acute psychosis)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Faktoriell oppgave
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Active control
Active control |
No APP based coaching, no human coaching, no rerandomization, no MRT |
|
Eksperimentell: App & Human Coaching + Continue Intervention
First-line of coaching: App + Human Coaching Responder |
Continue with existing intervention plan |
|
Eksperimentell: App & Human Coaching + Increase intensity in human coaching
First-line of coaching: App + Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Eksperimentell: App & Human Coaching + Booster
First-line of coaching: App + Human Coaching Non-Responder |
Add a booster session |
|
Eksperimentell: App Coaching + Continue Intervention
First-line of coaching: App Coaching Responder |
Continue with existing intervention plan |
|
Eksperimentell: App Coaching + Increase intensity in human coaching
First-line of coaching: App Coaching Non-Responder |
Increase intensity of human coaching |
|
Eksperimentell: App Coaching + Booster
First-line of coaching: App Coaching Non-Responder |
Add a booster session |
|
Eksperimentell: Human Coaching + Continue Intervention
First-line of coaching: Human Coaching Responder |
Continue with existing intervention plan |
|
Eksperimentell: Human Coaching + Increase intensity in human coaching
First-line of coaching: Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Eksperimentell: Human Coaching + Booster
First-line of coaching: Human Coaching Non-Responder |
Add a booster session |
|
Eksperimentell: No Coaching + Continue Intervention
First-line of coaching: No Coaching Responder |
Continue with existing intervention plan |
|
Eksperimentell: No Coaching + Increase intensity in human coaching
First-line of coaching: No Coaching Non-Responder |
Increase intensity of human coaching |
|
Eksperimentell: No Coaching + Booster
First-line of coaching: No Coaching Non-Responder |
Add a booster session |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Stress
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
10-item Perceived Stress Scale; each item will be rated from 0=Never to 4=Very often. Total scores range from 0 to 40. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Depression
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Patient Health Questionnaire-9; Each item will be rated from 0=Not at all to 3=nearly everyday. Total scores range from 0 to 27 |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Sleep Quality
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Pittsburgh Sleep Quality Index; each item will be rated from 0=No difficulty to 3=Severe difficulty. Total scores range from 0 to 21. Higher scores indicating poorer sleep quality |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Anxiety
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Generalised Anxiety Disorder; each item will be rated from 0=not at all to 3=nearly every day. Total score range from 0 to 21. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Tidsramme: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Lawton Instrumental Activities of Daily Living; each item will be rated 0=dependent to 1=independent. Total scores range from 0 to 8. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Tidsramme: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Activities of Daily Living; each item will be rate from 0=dependent to 5/10=independent. Total scores range from 0 to 100. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Symptoms
Tidsramme: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Wahler Physical Symptoms Inventory; each item will be rated from 0=almost never agree to 5=agree almost every day. Total score range from 0 to 210. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Chronic Illness
Tidsramme: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Participants will indicate any presence of chronic illness (e.g., diabetes, asthma, high blood pressure). |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Caregiver Burden
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
12-item Zarit Burden Interview Scale ; each item will be rated from 0=Never to 4=Nearly always. Total scores range from 0 to 48. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Psychological Well-Being
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
18-item Ryff Psychological Well-Being scale, each item range from 1-strongly agree to 7-strongly disagree. Total score range from 18-126. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical and Mental Health
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
5-level EQ-5D version (EQ-5D-5L) will be utilized; the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Neuropsychiatric
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Neuropsychiatric Inventory Questionnaire; classified each of the 12 domain into presence of symptom, frequency, severity, and caregiver distress. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Memory and Behaviour Problems
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Memory and Behavior Problems Checklist; a 24-item checklist from 0=never occurred/not at all to 4=daily/extremely. Higher score indicate more frequent behavioral problems/caregiver distress |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Caregiving
Tidsramme: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Scale for Caregiving Self-efficacy; 15-item scale. Total score is 100. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kee Lee Chou, PhD, The Education University of Hong Kong
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 2023-2024-0387
- 22231921 (Annet stipend/finansieringsnummer: Research Fund Secretariat, Health Bureau)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .